NCT01966003 - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

642

Participants

Timeline

Start Date

November 11, 2013

Primary Completion Date

July 23, 2015

Study Completion Date

July 23, 2015

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG

Carboplatin

Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W

DRUG

Paclitaxel

Administered 200 mg/m² IV Q3W

DRUG

ABP 215

Administered 15 mg/kg Q3W by IV infusion

DRUG

Bevacizumab

Administered 15 mg/kg Q3W by IV infusion

Trial Locations (4)

Research Site, Veliko Tarnovo

Research Site, Fremantle

Research Site, Rousse

Research Site, Bismarck